Protagonist Therapeutics, Inc.
PTGXNASDAQHealthcare● Active
$98.03
+$0.65(+0.67%)
Market Cap$6.3B
P/E Ratio—
52W High$107.84
52W Low$49.38
Protagonist Therapeutics, Inc. (PTGX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PTGX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.05
Est. -$0.65 · +107.7%
Revenue
$0.06B
Est. $0.01B · +381.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
PTGX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $2.43 | — | — | — | $0.21B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.65 | $0.05 | +107.7% | $0.06B | $0.01B | +381.7% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$0.53 | -$0.69 | -30.2% | $0.01B | $0.01B | -14.9% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.59 | -$0.62 | -5.1% | $0.00B | $0.01B | -68.4% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.53 | -$0.55 | -3.8% | $0.01B | $0.01B | -34.2% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.50 | -$0.19 | +62.0% | $0.03B | $0.01B | +332.0% |
| ▲ Q1 FY2025 | Feb 21, 2025 | $0.06 | $1.98 | +3200.0% | $0.17B | $0.08B | +110.6% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.59 | -$0.54 | +8.5% | $0.00B | $0.04B | -88.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$2.43
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.05
EPS Est.
-$0.65
EPS Surpr.
+107.7%
Revenue
$0.06B
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$0.69
EPS Est.
-$0.53
EPS Surpr.
-30.2%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.59
EPS Surpr.
-5.1%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.53
EPS Surpr.
-3.8%
Revenue
$0.01B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.50
EPS Surpr.
+62.0%
Revenue
$0.03B
Q1 FY2025
Feb 21, 2025Beat
EPS Actual
$1.98
EPS Est.
$0.06
EPS Surpr.
+3200.0%
Revenue
$0.17B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.54
EPS Est.
-$0.59
EPS Surpr.
+8.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.06 | $0.21 | $0.33 | 2 |
| Q3 FY2027 | $-0.21 | $-0.14 | $-0.04 | 2 |
| Q2 FY2027 | $-0.30 | $-0.20 | $-0.06 | 2 |
| Q1 FY2027 | $-0.35 | $-0.23 | $-0.07 | 2 |
| Q4 FY2026 | $0.03 | $0.09 | $0.14 | 4 |
| Q3 FY2026 | $-0.37 | $1.81 | $2.87 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +107.7% | $99.52 | $99.21 | -0.31% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -30.2% | $87.39 | $87.10 | -0.33% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -5.1% | $77.88 | $79.78 | +2.44% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -3.8% | $53.90 | $53.87 | -0.06% |
| ▲ Q2 FY2025 | May 6, 2025 | +62.0% | $44.28 | $42.01 | -5.13% |
| ▲ Q1 FY2025 | Feb 21, 2025 | +3200.0% | $38.49 | $38.75 | +0.68% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +8.5% | $47.60 | $47.61 | +0.02% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $35.79 | $36.21 | +1.17% |
Q2 FY2026-0.31%
Report Date
May 5, 2026
EPS Beat/Miss
+107.7%
Price Before
$99.52
Price After
$99.21
Q1 FY2026-0.33%
Report Date
Feb 25, 2026
EPS Beat/Miss
-30.2%
Price Before
$87.39
Price After
$87.10
Q4 FY2025+2.44%
Report Date
Nov 6, 2025
EPS Beat/Miss
-5.1%
Price Before
$77.88
Price After
$79.78
Q3 FY2025-0.06%
Report Date
Aug 6, 2025
EPS Beat/Miss
-3.8%
Price Before
$53.90
Price After
$53.87
Q2 FY2025-5.13%
Report Date
May 6, 2025
EPS Beat/Miss
+62.0%
Price Before
$44.28
Price After
$42.01
Q1 FY2025+0.68%
Report Date
Feb 21, 2025
EPS Beat/Miss
+3200.0%
Price Before
$38.49
Price After
$38.75
Q4 FY2024+0.02%
Report Date
Nov 7, 2024
EPS Beat/Miss
+8.5%
Price Before
$47.60
Price After
$47.61
Q3 FY2024+1.17%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$35.79
Price After
$36.21
Avg Beat Reaction-0.71%
Avg Miss Reaction+0.68%
Beat Rate5 / 8 quarters
Largest Move-5.13% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PTGX ends December
Protagonist Therapeutics, Inc. (PTGX) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.05 — beating the analyst consensus of $-0.65 by +107.7%. The next PTGX earnings date is expected around September 1, 2026.
Each quarter, investors track PTGX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PTGX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PTGX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PTGX earnings · 5 questionsProtagonist Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PTGX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PTGX historically reports after market close (AMC).
PTGX earnings datewhen is PTGX earningsPTGX next earnings datewhen does PTGX report earningsPTGX earnings calendar
▸ Source: FMP · Protagonist Therapeutics, Inc. SEC filings · US GAAP · Protagonist Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026